Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China
NEW YORK and MELBOURNE, Australia, Nov. 26, 2018 (GLOBE NEWSWIRE) — Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced […]